1AD (ASX) BIO24: So that's a wrap

1AD

Click for more information

0.00%

2.1¢ adalta limited

First 2 Last

Share
Profile

Follow
kranski1977

147 Posts.

14

18/06/24

00:11

Post #: 74360272
Share

Originally posted by waynesworld: ↑

BIO24 has come and gone but its impact may be enduring. According to the LinkedIn post by the CEO, BIO24 was very successful both in advancing AD-214 partnering discussions and getting the thumbs up for AdCella. My understanding is that the 1AD meeting schedule was chock-a-block over the 4 day event. We will undoubtedly get some colour about the event and its significance for AdAlta in the coming weeks but as we all know the only question for shareholders is, as far as AD-214 is concerned, are we there yet.

Presumably, a Trading Halt will eventually answer that question. In the meantime it would appear that we are taking significant strides in that direction. My own impression from all the data points to date, the investor meetings and the move to initiate AdCella and the east to west cellular immunotherapy strategy is that a good deal is close at hand. Not any deal but a good deal. Confidence comes from the fact that AdCella is advancing off the back of AdSolis and more specifically the opportunity to advance AD-214 into Phase 2.

If we were close prior to BIO24 maybe the temperature has now increased along with the competitive tension to secure a deal for a novel drug that could be transformative in a critical area of unmet need. Risk most certainly, but with an enterprise value of $10m an unbelievable investment opportunity. Remember that $1.9m was raised at a 20% premium to the closing price for the 1ADOA options.

Expand

Originally posted by waynesworld: ↑

BIO24 has come and gone but its impact may be enduring. According to the LinkedIn post by the CEO, BIO24 was very successful both in advancing AD-214 partnering discussions and getting the thumbs up for AdCella. My understanding is that the 1AD meeting schedule was chock-a-block over the 4 day event. We will undoubtedly get some colour about the event and its significance for AdAlta in the coming weeks but as we all know the only question for shareholders is, as far as AD-214 is concerned, are we there yet.

Presumably, a Trading Halt will eventually answer that question. In the meantime it would appear that we are taking significant strides in that direction. My own impression from all the data points to date, the investor meetings and the move to initiate AdCella and the east to west cellular immunotherapy strategy is that a good deal is close at hand. Not any deal but a good deal. Confidence comes from the fact that AdCella is advancing off the back of AdSolis and more specifically the opportunity to advance AD-214 into Phase 2.

If we were close prior to BIO24 maybe the temperature has now increased along with the competitive tension to secure a deal for a novel drug that could be transformative in a critical area of unmet need. Risk most certainly, but with an enterprise value of $10m an unbelievable investment opportunity. Remember that $1.9m was raised at a 20% premium to the closing price for the 1ADOA options.

Expand

1AD Price at posting: 2.6¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

SKS

SKS secures $20M for extension works on Melbourne data centre

BOE

Boss Energy ramps up as industrial-scale plant build continues; FY25 guidance of 850Klb intact

GDP grows 0.2% in June quarter, but annual growth the slowest since the 1990s

EBR

EBR Systems' heart pacing device on-target to reach the US market

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

There are more pages in this discussion • 5 more messages in this thread...

First 2 Last

Add 1AD (ASX) to my watchlist

(20min delay)
Last 2.1¢		Change 0.000(0.00%)		Mkt cap ! $12.50M

Open	High	Low	Value	Volume
2.1¢	2.1¢	2.0¢	$6.875K	336.9K

Buyers (Bids)

No.	Vol.	Price($)
1	176841	2.0¢

Sellers (Offers)

Price($)	Vol.	No.
2.2¢	950000	2

View Market Depth

No.	Vol.	Price($)
1	176841	0.020
5	936686	0.019
4	378423	0.018
1	1000000	0.017
1	62561	0.016

Price($)	Vol.	No.
0.022	950000	2
0.024	442693	4
0.025	207556	3
0.026	100000	1
0.027	100000	1

Last trade - 13.58pm 04/09/2024 (20 minute delay)

1AD (ASX) Chart

SKS secures $20M for extension works on Melbourne data centre

Boss Energy ramps up as industrial-scale plant build continues; FY25 guidance of 850Klb intact

GDP grows 0.2% in June quarter, but annual growth the slowest since the 1990s

EBR Systems' heart pacing device on-target to reach the US market

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Top Stories

SKS secures $20M for extension works on Melbourne data centre

Boss Energy ramps up as industrial-scale plant build continues; FY25 guidance of 850Klb intact

GDP grows 0.2% in June quarter, but annual growth the slowest since the 1990s

EBR Systems' heart pacing device on-target to reach the US market

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News